Previous 10 | Next 10 |
2024-03-18 06:46:25 ET Summary I have been actively reshaping my portfolio by selling off low-conviction holdings and focusing on high-growth compounders. I have reduced my holdings from roughly 90 to roughly 70 over the past 6 months or so. I am excited about my current alloc...
2024-03-17 17:09:16 ET More on AbbVie, Evolus, etc. AbbVie Inc. (ABBV) Barclays 26th Annual Global Healthcare Conference (Transcript) AbbVie: Comeback Expected After Humira Patent Expiration AbbVie Stock: I Was So Wrong, But This Is Way Too Fast Evolus prices...
2024-03-17 08:15:00 ET Finding high-yielding companies isn't everything when investing in dividend stocks. Sometimes, companies' yields increase after their share prices drop significantly, which can occasionally be a sign that the business could be in trouble and may have to decrease its p...
2024-03-15 15:30:34 ET Summary What's all the fuss about? Schwab U.S. Dividend Equity ETF™ provides stable income and long-term capital appreciation, but may underperform in terms of growth. The SCHD ETF is invested in 104 diversified holdings across various sectors, with t...
2024-03-14 14:09:10 ET AbbVie Inc. (ABBV) Barclays 26th Annual Global Healthcare Conference Call March 14, 2024 09:00 ET Company Participants Rob Michael - President & Chief Executive Officer Scott Reents - Executive Vice President & Chief Financer Roopal...
2024-03-14 11:22:56 ET More on Coherus BioSciences Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript Coherus BioSciences: FDA Approvals Spice Up The Pipeline Coherus BioSciences Q4 2023 Earnings Preview Biggest stock movers today: Boeing, NuSt...
2024-03-13 08:10:58 ET Summary US stocks climbed higher in February with the DJIA adding 0.4% and the S&P closing in on the 5,000-point mark. Interest rates were kept steady again in a range of 5.25% to 5.5%, with the market now projecting fewer hikes this year as the economy ...
2024-03-11 19:11:51 ET Summary Intra-Cellular Therapies' flagship drug, CAPLYTA, saw a 63% increase in the number of psychiatrists prescribing it in 2023. The company is seeking FDA approval to expand CAPLYTA's use to treat Major Depressive Disorder. CAPLYTA's growing acceptan...
2024-03-11 11:53:40 ET Summary Positive interim results released from phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. Functional and strength data from the phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients...
2024-03-10 12:23:46 ET Summary AbbVie's full-year results for 2023 might have been weak, but its price is still up by 15% YTD. The disconnect is explained by the revenue dip because of patent expiration for its blockbuster drug Humira, though revenues-ex Humira saw healthy growth....
News, Short Squeeze, Breakout and More Instantly...
QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults Canada NewsWire QULIPTA is now the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved to prevent migraine across...
2024-05-05 13:44:00 ET It's been more than a year since AbbVie (NYSE: ABBV) lost patent exclusivity for its most important product, Humira, an immunology medicine. Though this was a long time coming, the market reacted as though it was unexpected: AbbVie's shares dropped once the ma...
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.32% on an annualized basis producing an average annual return of 11.69%....